The Angiotensin II Type 1 Receptor-Associated Protein Attenuates Angiotensin II-Mediated Inhibition of the Renal Outer Medullary Potassium Channel in Collecting Duct Cells

Adjustments in renal K+ excretion constitute a central mechanism for K+ homeostasis. The renal outer medullary potassium (ROMK) channel accounts for the major K+ secretory route in collecting ducts during basal conditions. Activation of the angiotensin II (Ang II) type 1 receptor (AT1R) by Ang II is known to inhibit ROMK activity under the setting of K+ dietary restriction, underscoring the role of the AT1R in K+ conservation. The present study aimed to investigate whether an AT1R binding partner, the AT1R-associated protein (ATRAP), impacts Ang II-mediated ROMK regulation in collecting duct cells and, if so, to gain insight into the potential underlying mechanisms. To this end, we overexpressed either ATRAP or β-galactosidase (LacZ; used as a control), in M-1 cells, a model line of cortical collecting duct cells. We then assessed ROMK channel activity by employing a novel fluorescence-based microplate assay. Experiments were performed in the presence of 10−10 M Ang II or vehicle for 40 min. We observed that Ang II-induced a significant inhibition of ROMK in LacZ, but not in ATRAP-overexpressed M-1 cells. Inhibition of ROMK-mediated K+ secretion by Ang II was accompanied by lower ROMK cell surface expression. Conversely, Ang II did not affect the ROMK-cell surface abundance in M-1 cells transfected with ATRAP. Additionally, diminished response to Ang II in M-1 cells overexpressing ATRAP was accompanied by decreased c-Src phosphorylation at the tyrosine 416. Unexpectedly, reduced phospho-c-Src levels were also found in M-1 cells, overexpressing ATRAP treated with vehicle, suggesting that ATRAP can also downregulate this kinase independently of Ang II-AT1R activation. Collectively, our data support that ATRAP attenuates inhibition of ROMK by Ang II in collecting duct cells, presumably by reducing c-Src activation and blocking ROMK internalization. The potential role of ATRAP in K+ homeostasis and/or disorders awaits further investigation.

Adjustments in renal K + excretion constitute a central mechanism for K + homeostasis. The renal outer medullary potassium (ROMK) channel accounts for the major K + secretory route in collecting ducts during basal conditions. Activation of the angiotensin II (Ang II) type 1 receptor (AT1R) by Ang II is known to inhibit ROMK activity under the setting of K + dietary restriction, underscoring the role of the AT1R in K + conservation. The present study aimed to investigate whether an AT1R binding partner, the AT1R-associated protein (ATRAP), impacts Ang II-mediated ROMK regulation in collecting duct cells and, if so, to gain insight into the potential underlying mechanisms. To this end, we overexpressed either ATRAP or β-galactosidase (LacZ; used as a control), in M-1 cells, a model line of cortical collecting duct cells. We then assessed ROMK channel activity by employing a novel fluorescence-based microplate assay. Experiments were performed in the presence of 10 −10 M Ang II or vehicle for 40 min. We observed that Ang II-induced a significant inhibition of ROMK in LacZ, but not in ATRAP-overexpressed M-1 cells. Inhibition of ROMK-mediated K + secretion by Ang II was accompanied by lower ROMK cell surface expression. Conversely, Ang II did not affect the ROMK-cell surface abundance in M-1 cells transfected with ATRAP. Additionally, diminished response to Ang II in M-1 cells overexpressing ATRAP was accompanied by decreased c-Src phosphorylation at the tyrosine 416. Unexpectedly, reduced phospho-c-Src levels were also found in M-1 cells, overexpressing ATRAP treated with vehicle, suggesting that ATRAP can also downregulate this kinase independently of Ang II-AT1R activation. Collectively, our data support that ATRAP attenuates inhibition of ROMK by Ang II in collecting duct cells, presumably by reducing c-Src activation and blocking ROMK internalization. The potential role of ATRAP in K + homeostasis and/or disorders awaits further investigation.
Keywords: K + homeostasis, K + channels, angiotensin II type 1 receptor, c-Src, angiotensin II type 1 receptorassociated protein, kidney INTRODUCTION Appropriate regulation of K + content in the extracellular fluid is critical for cell function, especially for excitable tissues, since the K + gradient largely determines resting membrane potential (Unwin et al., 2011). Accordingly, many different acute and chronic mechanisms are now recognized to play a role in K + homeostasis (Mcdonough and Youn, 2017) in such a way that blood K + levels tend to vary slightly throughout the day (Moore-Ede, 1986). The task of maintaining short-and longterm K + balance is mainly achieved by kidneys, which properly regulate K + content in urine in response to the physiological status. Indeed, kaliuresis can be as high as ~150% or as low as ~2% of total filtered potassium (Unwin et al., 2011). By doing so, kidneys can respond to critical situations of ion excess or restriction.
Seminal studies by Giebisch, Malnic, and Klose during the 1960s have shown the crucial role of distal nephron to the regulated kaliuresis under different experimental conditions (Malnic et al., 1964). They have found that the proximal tubule and the Henle of Loop segments reabsorb ~90% of all filtered K + , regardless of the amount of K + contained in the diet. On the other hand, the appropriate regulation of renal losses occurs in the downstream segments by further K + reabsorption or secretion from the peritubular space (Malnic et al., 1964).
The renal outer medullary potassium (ROMK) channel comprises the major constitutive pathway for renal K + secretion (Wang and Giebisch, 2009;Welling and Ho, 2009), thereby playing an essential role in K + homeostasis. Under the setting of K + restriction, K + homeostasis can be maintained at least in part by inhibition of ROMK in the collecting duct via coupling of angiotensin II (Ang II) to its Ang II type 1 receptor (AT1R; Wei et al., 2007). Ang II/AT-1R induces oxidative stress and enhances the levels of total and phosphorylated c-Src, which ultimately inhibits ROMK by its phosphorylation at a tyrosine residue (Wei et al., 2007;Yue et al., 2011). Accordingly, AT1R is locally upregulated in collecting ducts during low K + -diets (LK; Wei et al., 2007), and AT1R inhibition during LK diets impairs renal K + conservation (Jin et al., 2009), underlining the importance of renin-angiotensin-system for K + homeostasis.
Several studies have pointed out that AT1R signaling is modulated by associated proteins, particularly the AT1Rassociated protein (ATRAP). ATRAP colocalizes in vivo with AT1R in all nephron segments, from the Bowman's capsule to the inner medullary collecting duct cells (Tsurumi et al., 2006). It has been shown that ATRAP is often an inhibitory partner of AT1R by, at least in part, impairing G-protein coupling to the receptor (Lopez-Ilasaca et al., 2003). However, it has also been reported that ATRAP can potentiate, instead of inhibiting, AT1R-mediated effects (Barro-Soria et al., 2012) and that ATRAP may also induce AT1R-independent actions (Mederle et al., 2016). The impact of ATRAP on AT1R/Ang II-mediated sodium homeostasis has been previously shown (Wakui et al., 2013;Ohsawa et al., 2014).
However, the potential role of ATRAP on Ang II-regulation of K + homeostasis remains to be established. Therefore, the present study aimed to test the hypothesis that ATRAP impacts Ang II-mediated ROMK regulation and if so, to gain insight into the potential underlying mechanisms.

Cell Culture
M-1 collecting duct cells (ATCC CRL-2038) were kindly provided by Dr. Per Svenningsen (University of South Denmark, Denmark) and maintained in 25-cm 2 tissue culture flasks in a 1:1 mixture of Dulbecco's modified Eagle's medium/Ham's F12 medium (DMEM/F12) supplemented by 100 U/ml penicillin, 100 μg/ ml streptomycin, 0.5 mM sodium pyruvate, 5 μM dexamethasone, and 5% (v/v) heat-inactivated fetal bovine serum (FBS) as recommended by the supplier. Cultures were incubated in a humidified 95% air-5% CO 2 atmosphere at 37°C and subcultured by 0.25% trypsin-EDTA. Cells were seeded onto 24-well microplates for immunoblotting experiments or 96-well microplates for FluxOR assay experiments. Non-transfected cells were grown to confluence and then serum-starved for at least 72 h. Lysates from M-1 cells were immunoblotted with antibodies against the α subunit of ENaC and ROMK for cell line characterization (Figures 1A,B). Band sizes were predicted based on previous evidence (Hu et al., 2009;Murthy et al., 2016;Shimizu et al., 2017).

FluxOR Assay
Renal outer medullary potassium channel activity was assessed by a fluorescence-based microplate assay (FluxOR II Green Potassium Ion Channel Assay). The assay is based on the fact that thallium influx serves as a surrogate for K + channel and transporter activity and takes advantage of recently developed thallium-sensitive fluorophores (Beacham et al., 2010). The FluxOR assay was performed using the washing method recommended by the supplier, and bottom fluorescence intensity was assessed by end-point readout in the SynergyH1 microplate reader (Biotek, Winooski, VT).

Cell Surface Biotinylation
Cell surface biotinylation was performed to assess ROMK expression in the plasma membrane, as previously described (Carraro-Lacroix et al., 2010). LacZ-and ATRAP-overexpressing M-1 cells cultivated in six-well plates were treated with 10 −10 M Ang II for 40 min before biotinylation protocol as previously described in detail (Carneiro De Morais et al., 2015). Biotinylated cells were then lysed by a modified RIPA buffer (150 mM NaCl, 50 mM Tris·HCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 5 mM EDTA, pH 7.4) and 300 μg of the total cellular extract were incubated with 50 μl streptavidincoupled agarose beads (#20347, ThermoFisher). After overnight incubation, streptavidin beads were washed with RIPA buffer for 15 min, followed by centrifugation at 10.000 rpm for 5 min. This washing step was repeated three times. Biotinylated proteins were then denatured from streptavidin beads by adding modified Laemmli buffer (2% SDS, 20% glycerol, 100 mM DTT, 0.1% bromophenol blue, 50 mM Tris, and pH 6.8) and heating samples at 98°C for 3 min. Solubilized biotinylated proteins were submitted to SDS-PAGE. Finally, we have also used 10 μg of the total cellular extract from each sample to assess total ROMK and GAPDH expression.

Statistical Analysis
Data are presented as mean ± SE. Statistical analyses were performed using GraphPad Prism 7.04. Groups were tested for normality by the Shapiro-Wilk test and homoscedasticity by the Brown-Forsythe test. When comparing three or more Frontiers in Physiology | www.frontiersin.org groups, we used a parametric ANOVA test followed by Bonferroni post hoc test or nonparametric Kruskal-Wallis followed by Dunn's post hoc test. For comparison between two groups, we used an unpaired t-test.

RESULTS
Ang II Inhibits ROMK Activity in M-1 Cells To assess whether K + transport in M-1 cells was responsive to Ang II, we employed the FluxOR assay, as described in Materials and Methods. Experiments were conducted in the presence or absence of the ROMK inhibitor VU591. As seen in Figure 2A, the K + conductance in non-transfected M-1 cells, measured as the thallium-induced fluorescence, was similarly reduced by Ang II at concentrations ranging from 10 −9 to 10 −12 M. The concentration of 10 −10 M Ang II was chosen to be used in the subsequent experiments, an average urinary concentration of Ang II (Wang et al., 2003).
In order to assess whether the Ang II-mediated effect on K + conductance was induced by AT1R activation, M-1 cells were then pretreated with telmisartan (10 −8 M) before exposing cells to vehicle or Ang II (10 −10 M). As observed in Figure 2B, telmisartan pretreatment abrogates Ang II-induced inhibition of K + conductance. Finally, M-1 cells were also treated with Ang II or vehicle for 40 min in the presence or absence of 10 μM VU591. As illustrated in Figure 2C, the VU591 compound reduced K + conductance by ~45 ± 3% in comparison with vehicle-treated cells, underlining the critical role of the ROMK channel in apical K + conductance in M-1 cells. Similar to the findings of Figure 2A, Ang II decreased K + conductance by ~30 ± 6% compared to vehicle-treated M-1 cells. Importantly, VU591 and Ang II cotreatment did not induce an additive inhibitory effect on K + conductance, supporting the notion that Ang II-mediated modulation of K + transport in M-1 cells is due to the regulation of ROMK activity.

ATRAP Overexpression Attenuates the Ang II Inhibitory Effect on ROMK
The efficiency of M-1 transfection was evaluated by the emission of fluorescence in mock-or GFP-transfected M-1 cells and the efficacy of overexpression of ATRAP and recombinant β-LacZ was confirmed by immunoblotting using an anti-V5 antibody (Figures 3A,B). We then sought to examine the effect of overexpressing ATRAP in the Ang II-mediated ROMK inhibition in M-1 cells. As seen in Figure 3C, Ang II significantly reduced ROMK activity in control LacZ-M-1 cells (~29 ± 9%, p < 0.05), but not in ATRAP-overexpressing cells (~15 ± 2%), when compared to vehicle-treated LacZ-overexpressing M-1 cells.
Interestingly, a significant part of this discrete inhibitory effect in K + conductance observed in ATRAP-overexpressing M-1 cells is present at baseline conditions (8 ± 3% inhibition vs. vehicletreated LacZ-overexpressing cells). In fact, when this difference at basal levels is taken into account, the magnitude of ROMK inhibition mediated by Ang II in ATRAP-overexpressing cells is only 7 ± 3% when compared to vehicle-treated ATRAPoverexpressing cells, an effect significantly smaller than that observed in LacZ-overexpressing cells ( Figure 3D). These data collectively suggest that ATRAP overexpression attenuates Ang II-inhibition of ROMK but does not increase K + conductance at basal conditions.

ATRAP Overexpression Blunts Ang II-Induced Decrease of Cell Surface ROMK Expression
To assess whether the decrease of Ang II-induced inhibition of ROMK in ATRAP-overexpressing cells was associated with a reduction in ROMK expression at the plasma membrane, we evaluated ROMK expression plasma membrane by cell surface biotinylation. As presented in Figures 4A,B, after acute treatment with Ang II, Lac-Z overexpressing cells, but not ATRAPoverexpressing cells, showed a significant decrease in the ratio of surface ROMK to total ROMK expression, when compared to vehicle-treated LacZ-overexpressing cells (43 ± 8%, p < 0.05). It was observed that Ang II treatment caused a reduction of ROMK cell surface expression in only one out of four samples from ATRAP-overexpressing cells. As seen in Figure 4C, the mean Ang II-induced effect on reducing plasma membrane ROMK expression was just 6 ± 10% in the ATRAP-overexpressing group (p < 0.05 vs. LacZ-overexpressing cells). Finally, we also assessed total ROMK expression normalized to GAPDH expression, and no difference was observed among experimental groups ( Figure 4D).

ATRAP Attenuates Activation of c-Src in the Presence and Absence of Ang II
The activation of the c-Src kinase by phosphorylation of the tyrosine 416 residue constitutes the central molecular mechanism of ROMK inhibition by Ang II (Yue et al., 2011). Thus, we next assessed whether modulation of c-Src activation could underlie the diminished response to Ang II in M-1 cells overexpressing ATRAP compared with LacZ-overexpressing M-1 cells. The representative immunoblot of phospho-c-Src in ATRAP and Lac-Z-overexpressed M-1 cells treated or not with 10-10 M Ang II is shown in Figure 5A. The phospho-c-Src levels were significantly elevated in LacZ-overexpressing M-1 cells treated with Ang II vs. vehicle-treated LacZ-overexpressing M-1 cells (Figures 5A,B). In contrast, phosphorylation of c-Src at tyrosine 416 significantly decreased in both vehicle-and Ang II-treated ATRAP-overexpressing M-1 cells compared to LacZ-overexpressing M-1 cells (Figures 5A,B).

DISCUSSION
Understanding kaliuresis regulation is crucial since plasma K + levels need to be kept within a narrow range for vital cellular functions. As the median K + consumption in modern western diets is ~50% of the recommended intake (Chen et al., 2006), understanding how kidneys are able to decrease kaliuresis is particularly important. It is well established that AT1R upregulation in collecting duct cells with consequent ROMK inhibition constitutes an essential mechanism for K + conservation during low-K + diets. Indeed, it has been demonstrated that rats fed a low K + diet and simultaneously treated with losartan do not exhibit a decrease in the number of ROMK-like channels in their collecting ducts and exhibit a higher reduction in plasma potassium levels during potassium restriction (Jin et al., 2009). Our study provides new evidence that the angiotensin receptor-associated protein ATRAP impacts K + conductance in collecting duct cells. More specifically, ATRAP counteracts the Ang II-mediated ROMK internalization and consequent inhibition in a collecting cell culture model. This effect is accompanied by decreases in c-Src Y416 phosphorylation, a critical signaling pathway for ROMK inhibition by Ang II. Although p38 and ERK1/2 pathways seem to be part of AT1Rdependent inhibition of ROMK channels during LK diets Jin et al., 2009), tyrosine phosphorylation of ROMK by c-Src is the most important signaling pathway directly responsible for ROMK inhibition during potassium restriction. While collecting ducts from rats fed LK diets do not show relevant ROMK-like small conductance K + currents, these same collecting ducts presented a significant increase in the number of ROMK-like channels in patch-clamp recordings when the collecting duct cells were acutely treated with c-Src inhibitor herbimicyn A for 30 min, an effect that does not occur in rats receiving HK diets (Wang et al., 2000(Wang et al., , 2010. Also, in the collecting ducts from animals receiving LK diets, the acute treatment with c-Src inhibitor herbymicin A majorly abolishes the Ang II inhibitory effect over ROMK activity (Wei et al., 2007). Accordingly, in the present study, diminished response to Ang II in M-1 cells overexpressing ATRAP was accompanied by a decrease in c-Src phosphorylation at the tyrosine 416. Interestingly, we have observed lower activation of c-Src even in the vehicle-treated ATRAP-M1 cells, suggesting that ATRAP not only inhibits Ang II-mediated c-Src signaling but also evokes Ang II/AT1R-independent modulation of this kinase. It has been previously shown that ATRAP can regulate signaling pathways in the absence of Ang II. Interestingly, ATRAP interacts with the multiscaffolding RACK1 (Wang et al., 2002), a protein that is also detected in AT1R immunocomplexes (Parent et al., 2008) and is associated with c-Src sequestration (Kiely et al., 2005). Since RACK1 is not an integral membrane protein, ATRAP might recruit RACK1 to the plasma membrane, which would favor c-Src inactivation, even without Ang II involvement. Albeit ATRAP overexpression per se decreased c-Src phosphorylation, we did not observe increased ROMK activity in the vehicle-treated ATRAP overexpressed-M1 cells. This finding could be expected considering the effect of c-Src inhibition by herbymicin A in collecting duct cells from animals fed an LK diet. Other AT1R-independent effects mediated by ATRAP or cellular compensatory mechanisms might take place in such a way that K + channel activity does not change in cells overexpressing ATRAP despite the reduction in c-Src activation. This observation resembles what was observed for the ATRAP-mediated effect on cardiomyocyte Ca 2+ signaling (Mederle et al., 2016). The authors found that ATRAP stimulates SERCA2a and accelerates calcium sequestration into the endoplasmic reticulum in vitro, which improves ventricular relaxing and filling. However, ATRAP knockout cells also had an unexpectedly lower basal intracellular Ca 2+ concentration, which led the authors to postulate that ATRAP could regulate other calcium homeostasis mechanisms at basal conditions. When these basal differences were not considered, the ATRAP effect over physiological relevant calcium transients was somewhat masked. Accordingly, when we take into account the modest basal variations of K + conductance between LacZ and ATRAPoverexpressing cells, the inhibitory effect of Ang II on ROMK is even lower in the ATRAP-overexpressing M-1 cells (7% inhibition in ATRAP-overexpressing group, in comparison to a 29% inhibitory effect of Ang II in LacZ-overexpressing cells).
It is known that ROMK inhibition by c-Src is not directly caused by channel phosphorylation. Previous studies demonstrated that ROMK inhibition by exogenous c-Src was only seen in cell-attached patches but not in isolated patches. This inhibitory effect was associated with phosphorylation of tyrosine 337 of the channel and was abolished by agents that inhibit endocytosis (Wang et al., 2000;Moral et al., 2001). Therefore, ROMK inhibition by c-Src is mediated by phosphorylation and consequent internalization of the channel. In line with these observations, we observed that Ang II treatment induced a significant decrease in plasma membrane expression of ROMK in LacZ-overexpressing cells, but not in ATRAP-overexpressing cells, and the level of changes observed in ROMK activity assay somehow resembles what we have observed in biotinylation experiments. It is worth mentioning that previous studies assessing ROMK inhibition by AT1R/ Ang II have deduced ROMK internalization by single-channel patch-clamp experiments and further analysis of NPo products (Wei et al., 2007;Jin et al., 2009;Wang et al., 2010). Therefore, the present study provides novel molecular evidence that Ang II reduces ROMK cell surface expression in collecting duct cells.
Whereas the ATRAP's impact on sodium balance and volemic homeostasis has been shown in different studies, particularly during Ang II-induced hypertension (Ohsawa et al., 2014), its implications for kaliuresis regulation are unknown. K + conservation through ROMK inhibition is an essential mechanism for K + homeostasis without evoking other electrolyte imbalances. When such a regulatory mechanism is not enough to maintain K + balance during LK diets, the consequent decreases of extracellular K + levels induce hyperactivation of NCC transporter, thus linking K + restriction to hypertension (Terker et al., 2015). Therefore, it is possible that differential regulation of ROMK by Ang II/AT1R and ATRAP in collecting ducts that we found here may have consequences in serum K + levels and could impact not only K + homeostasis but also pressure outcomes in K + -restricted diets. In this regard, Yap et al. (2017) have observed that the polymorphism A1166C at the 3'-UTR of the AT1R gene correlates with alterations in blood pressure that seems dependent on K + intake in healthy Malaysian adults. Subjects with the genotype AA, associated with lower FIGURE 6 | Schematic representation of ATRAP-mediated actions on c-Src phosphorylation status, ROMK expression at the plasma membrane, and ROMK activity. M-1 cells overexpressing control LacZ protein has a decreased K + conductance after Ang II treatment, an effect that was associated with lower expression of ROMK at the plasma membrane and induction of c-Src phosphorylation, the classical signaling pathway for ROMK inhibition by Ang II. Conversely, M-1 cells overexpressing the ATRAP do not show significant decreases in K + conductance after Ang II treatment and plasma membrane ROMK expression, which was also associated with a blunted response of c-Src phosphorylation.
expression of AT1R (Sethupathy et al., 2007;Chandra et al., 2014), showed higher systolic and diastolic blood pressure when their K + intakes were low. Also, He et al. (2011) observed that this genotype was also associated with higher blood pressure decline after potassium supplementation in Chinese subjects. It remains to be established whether such changes in blood pressure during dietary K + restriction may also be associated with genetic variations in other RAS components, including ATRAP. The impact of differential regulation of ATRAP on ROMK regulation and, consequently, on K + homeostasis and blood pressure control could resemble some effects of losartan treatment observed during poor-K + diets (Jin et al., 2009). As aforementioned, losartan treatment increases kaliuresis and exacerbates hypokalemia during the LK diet in rats (Jin et al., 2009). This condition could also upregulate NCC activity and, by doing so, attenuate the natriuretic effect of such a drug. Interestingly, the K + -rich DASH diet amplifies losartan treatment response, particularly in African-American subjects, so that the combined treatment is more than additive (Conlin et al., 2003). It is known that African-Americans represent a population that has diminished blood pressure response to AT1 receptor blockers and, at the same time, increased blood pressure response to thiazides (Brewster and Seedat, 2013). Notably, a genetic study reported that, for African-American women, such increased thiazide response was associated with the genotype AA of the polymorphism A1166C (Frazier et al., 2004). Taking these studies into account and considering ATRAP effects on ROMK regulation, the classical hypotensive effect of ATRAP reported in normal-K + diets could be blunt during diets with a modest or more severe K + restriction.
On the other hand, during HK diets, ATRAP might be an important component determining the K + secretion capacity of collecting ducts. Interestingly, Wei et al. (2014) observed that CCDs from rats submitted to HK rats and pretreated with AT2R antagonists did not show a decreased ROMK activity after AngII treatment. This observation suggests that collecting duct AT1R during HK settings is not responsive to modulate ROMK activity. Notably, AT1R expression, assessed at the transcriptional level, was not decreased during the HK diet. It would be interesting to evaluate further whether ATRAP is upregulated in CCDs during HK diets, which might explain these previous observations made by Wei and colleagues. Although our in vitro observations give us direct evidence of ATRAP's ability to attenuate AT1R-mediated ROMK inhibition, further in vivo works will be important for assessing how ATRAP is modulated during changes in potassium intake and how CCD-specific ATRAP transgenic animals respond to potassium dietary changes, for instance. These analyses will address ATRAP's physiological impact on potassium balance and might help us to explain previous physiological observations in this field.
In conclusion, our study demonstrates that ATRAP can counteract Ang II-mediated inhibition of ROMK activity and might then be a relevant protein regulating K + handling. As depicted in Figure 6, K + conductance is inhibited in Frontiers in Physiology | www.frontiersin.org 9 May 2021 | Volume 12 | Article 642409 LacZ-overexpressing M-1 cells treated with Ang II. In contrast, this response is blunted in M1 cells overexpressing ATRAP. Accordingly, this differential response is accompanied by a decrease in the expression of ROMK channels at the plasma membrane of LacZ-overexpressing M-1 cells, but not in ATRAPoverexpressing cells. Finally, blunted response to Ang II in ATRAP-overexpressing M1 cells is associated with diminished c-Src phosphorylation signaling, a pathway that seems to be critically involved in ROMK endocytosis. Future studies should be performed in animal models to evaluate the impact of differential ATRAP expression in K + homeostasis during different changes of K + dietary content. Moreover, it would be interesting to assess how polymorphisms in ATRAP could be associated with changes in plasma K + levels and/or in blood pressure during K + -poor diets in different human populations.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS
AG and NR designed the study. JP carried out the experiments, analyzed the data, wrote the manuscript, and prepared the figures. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by grants 2013/11093-0 and 2016/22140-7 from the São Paulo Research Foundation (FAPESP) and by the Coordination for the Improvement of Higher Education Personnel (CAPES) -Finance Code 001.